文献速递淋巴瘤

新合并症指数与大型B细胞淋巴瘤嵌合抗原受体T细胞治疗后的生存相关

New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

研究基于国际血液与骨髓移植研究中心注册库2017至2020年接受商业化CD19 CAR-T治疗的1916例大型B细胞淋巴瘤患者,开发并验证细胞治疗合并症指数(CT-CI)。CT-CI评分越高总生存越差,且可预测治疗相关死亡和复发,但与CAR-T相关毒性无相关性。

要点

  • CT-CI将患者分为3类,评分越高死亡风险越高。
  • CT-CI≥3组死亡风险为参照组的2.55倍(95%CI 1.90-3.42)。
  • CT-CI与CAR-T相关毒性无相关性。

核心结论

  • 新型CT-CI评分可分层评估患者合并症对CAR-T治疗后生存的影响,可用于高危人群的临床决策和治疗选择。
  • 合并症和对毒性增加的担忧不应妨碍患者接受这一有效治疗。

研究设计与样本

  • 从国际血液与骨髓移植研究中心注册库选取2017至2020年接受商业化CAR-T治疗的18岁及以上大型B细胞淋巴瘤患者。
  • 患者随机分配至训练队列或验证队列,共纳入来自97个医疗中心的1916例患者,中位年龄64岁(范围19-91岁)。

主要发现

  • 约70%的患者有合并症,其中心脏病占12%、糖尿病占14%、轻度肝功能障碍占8%、中重度肝功能障碍占2%、精神障碍占18%、中度肺功能障碍占15%、重度肺功能障碍占12%。
  • CT-CI评分升高与死亡风险增加相关:CT-CI 1的HR为1.37(95%CI 1.16-1.62;P<.001),CT-CI 2的HR为1.49(95%CI 1.17-1.89;P=.001),CT-CI≥3的HR为2.55(95%CI 1.90-3.42;P<.001)。
  • 较高的CT-CI评分可预测治疗相关死亡和复发。
  • CT-CI评分与CAR-T相关毒性无相关性。

关键数值与推荐

  • CT-CI将患者分为3类,评分越高总生存越差。
  • CT-CI 1的HR为1.37(95%CI 1.16-1.62;P<.001);CT-CI 2的HR为1.49(95%CI 1.17-1.89;P=.001);CT-CI≥3的HR为2.55(95%CI 1.90-3.42;P<.001)。

临床怎么用

  • CT-CI评分可用于高危人群的临床决策和治疗选择。
  • 合并症和对毒性增加的担忧不应妨碍患者接受这一有效治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The cumulative impact of baseline comorbidities on outcomes of chimeric antigen receptor T-cell (CAR-T) therapy is not well established. Therefore, we developed and validated a Cellular Therapy Comorbidity Index (CT-CI) to predict outcomes following CD19-directed CAR-T therapy for large B-cell lymphoma (LBCL). Patients aged 18 or older receiving commercial CAR-T therapy for LBCL during 2017 to 2020 were selected from the Center for International Blood and Marrow Transplant Research registry. Patients were randomly assigned to training or validation cohorts. Comorbidities given weighted scores comprised the CT-CI, which was then validated for overall survival (OS) prognostication. A total of 1916 patients from 97 medical centers were included, with a median age of 64 years (19-91 years). About 70% of patients had comorbidities, such as cardiac disease (12%); diabetes (14%); hepatic dysfunction (mild, 8%; moderate to severe, 2%); psychiatric disturbance (18%); and pulmonary dysfunction (moderate, 15%; severe, 12%). The CT-CI was calculated, stratified patients in 3 categories, and was associated with increased mortality. Patients with higher CT-CI scores had worse OS (CT-CI 1: hazard ratio [HR], 1.37 [95% confidence interval [CI], 1.16-1.62; P < .001]; CT-CI 2: HR, 1.49 [95% CI, 1.17-1.89; P = .001]; CT-CI ≥ 3: HR, 2.55 [95% CI, 1.90-3.42; P< .001]). Higher CT-CI scores predicted treatment-related mortality and relapse. There was no correlation between the CT-CI score and CAR-T-related toxicities. The novel CT-CI score stratifies the effect of patient comorbidities on survival after CAR-T therapy and can be used for clinical decision-making and treatment selection in high-risk populations. However, comorbidities and fear of increased toxicity should not preclude patients from this effective therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Greenbaum U, Hashmi H, Elsawy M, et al. New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma. Blood Adv. 2026. PMID: 40811818. doi:10.1182/bloodadvances.2024015599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。